Guardant Health, Inc. presented data from a study demonstrating the strong performance of its methylation-based Shield multi-cancer detection (MCD) test. The study, presented at the 2025 American Association for Cancer Research (AACR) annual meeting, showed high specificity and clinically meaningful sensitivity across ten tumor types.
The Shield MCD test achieved 98.5% specificity and 60% overall sensitivity, with 74% sensitivity across the six most aggressive cancers, including esophageal-gastric, hepatocellular, lung, ovarian, and pancreas. The test also demonstrated 89% accuracy for primary or secondary cancer signal of origin (CSO) prediction.
AmirAli Talasaz, Guardant Health co-CEO, emphasized that this strong data reinforces the potential of the Shield test to detect multiple cancers earlier through a simple blood draw. The results served as the basis for the NCI's selection of the Shield MCD test for its upcoming Vanguard Study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.